The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes

被引:3
作者
Temiz, Mustafa Zafer [1 ]
Cakir, Omer Onur [1 ]
Aykan, Serdar [1 ]
Kucuk, Suat Hayri [2 ]
Tiryakioglu, Necip Ozan [3 ]
Bilek, Gunal [4 ]
Tunali, Nagehan Ersoy [5 ]
Kandirali, Engin [1 ]
Semercioz, Atilla [1 ]
机构
[1] Bagcilar Training & Res Hosp, Dept Urol, Bagcilar Istanbul, Catalca Istanbu, Turkey
[2] Bagcilar Training & Res Hosp, Dept Biochem, Bagcilar Istanbul, Turkey
[3] Istanbul Gelisim Univ, Coll Hlth Sci, J Kom Er Hakan Oner Sk 1, Avcilar, Turkey
[4] Bitlis Eren Univ, Dept Stat, Ahmet Eren Bulvari, Bitlis, Turkey
[5] Istanbul Medeniyet Univ, Dept Mol Biol & Genet, D-100 Karayolu 98, Kadikoy, Turkey
关键词
biomarkers; prostate cancer; prostate-specific antigen; zinc; CANCER DETECTION; HEALTH INDEX; CADMIUM; BENIGN; TISSUES; PLASMA; RISK;
D O I
10.2217/bmm-2018-0260
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aim: To generate a combination of serum zinc (Zn) and prostate-specific antigen (PSA) in an attempt to provide better prediction of prostate biopsy outcomes with Zn/PSA ratios. Materials & methods: Diagnostic performances of PSA and Zn/PSA were investigated using receiver operating characteristic and the area under the curve analysis and McNemar test in 480 men. Decision curve analysis was also used to determine the net clinical benefits of the two parameters. Results: The receiver operating characteristic-area under the curve analysis established a similar diagnostic performance for both parameters. Although Zn/PSA had a higher diagnostic sensitivity, PSA was superior in terms of specificity and net clinical benefits. Conclusion: Zn/PSA has no substantial superiority in the prediction of prostate biopsy outcomes.
引用
收藏
页码:59 / 68
页数:10
相关论文
共 28 条
[1]  
[Anonymous], UROL ONCOL
[2]   Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis [J].
Bruzzese, Dario ;
Mallarella, Claudia ;
Ferro, Matteo ;
Perdona, Sisto ;
Chiodini, Paolo ;
Perruolo, Giuseppe ;
Terracciano, Daniela .
TRANSLATIONAL RESEARCH, 2014, 164 (06) :444-451
[3]   Zinc and cadmium analysis in human prostate neoplasms [J].
Brys, M ;
Nawrocka, AD ;
Miekos, E ;
Zydek, C ;
Foksinski, M ;
Barecki, A ;
Krajewska, WM .
BIOLOGICAL TRACE ELEMENT RESEARCH, 1997, 59 (1-3) :145-152
[4]   Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547
[5]  
Cotter K, 2016, F1000RES, V5, DOI 10. 12688/f1000research. 7183. 1
[6]   Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging [J].
de Cobelli, Ottavio ;
Terracciano, Daniela ;
Tagliabue, Elena ;
Raimondi, Sara ;
Bottero, Danilo ;
Cioffi, Antonio ;
Jereczek-Fossa, Barbara ;
Petralia, Giuseppe ;
Cordima, Giovanni ;
Almeida, Gilberto Laurino ;
Lucarelli, Giuseppe ;
Buonerba, Carlo ;
Matei, Deliu Victor ;
Renne, Giuseppe ;
Di Lorenzo, Giuseppe ;
Ferro, Matteo .
PLOS ONE, 2015, 10 (10)
[7]  
El Fegoun AB, 2007, PROG UROL, V17, P165
[8]   ZINC AND CADMIUM PLASMA AND ERYTHROCYTE LEVELS IN PROSTATIC-CARCINOMA, BPH, UROLOGICAL MALIGNANCIES, AND INFLAMMATIONS [J].
FEUSTEL, A ;
WENNRICH, R .
PROSTATE, 1986, 8 (01) :75-79
[9]  
FEUSTEL A, 1987, UROL RES, V15, P161
[10]   Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis [J].
Filella, Xavier ;
Gimenez, Nuria .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (04) :729-739